

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC
Form 8-K
March 26, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 26, 2004

Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-30929
(Commission File Number)

13-4087132
(IRS Employer Identification No.)

750 Lexington Avenue
New York, New York 10022
(Address of principal executive offices)

(212) 531-5965
(Registrant's telephone number, including area code)

=====

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

The following exhibit is filed as a part of this report:

Exhibit Number	Description
-------------------	-------------

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

99.1

Press Release dated March 26, 2004.

Item 12. Results of Operations and Financial Condition

On March 26, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2003. Keryx also announced that it would host a conference call on March 26, 2004 for investors where Keryx will discuss its results of operations and financial results. A copy of such press release is attached to this current report on Form 8-K as Exhibit 99.1 and is being furnished under Item 12 of Form 8-K.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: March 26, 2004

By: /s/ Ron Bentsur

Ron Bentsur
Vice President - Finance
and Investor Relations

-3-

INDEX TO EXHIBITS

Exhibit Number	Description
-----	-----

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

99.1

Press Release dated March 26, 2004.

-4-